Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 2/20 | 0.58 |
| ▸ | MLYCD | O95822 | 2/20 | 0.56 |
| ▸ | TACR1 | P25103 | 6/20 | 0.55 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.51 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25779257 | 0.86 | MTOR (0.55) | MTORMLYCDTACR1P2RX1TMPRSS4 | |
| SCHEMBL4305835 | 0.83 | TACR1 (0.60) | MTORMLYCDTACR1P2RX1TMPRSS4 | |
| SCHEMBL11306116 | 0.83 | TACR1 (0.63) | MTORMLYCDTACR1P2RX1TMPRSS4 | |
| SCHEMBL31173731 | 0.83 | MLYCD (0.63) | MLYCDAURKARPS6KB1CYP2C19GAA | |
| SCHEMBL1052230 | 0.83 | MLYCD (0.63) | MLYCDAURKARPS6KB1CYP2C19GAA | |
| SCHEMBL15844016 | 0.82 | TACR1 (0.58) | MTORMLYCDTACR1P2RX1TMPRSS4 | |
| SCHEMBL6301053 | 0.81 | MTOR (0.58) | MTORMLYCDTACR1P2RX1TMPRSS4 | |
| SCHEMBL3897948 | 0.81 | CYP2C9 (0.59) | MTORAURKARPS6KB1CYP2C9CYP2C19 | |
| SCHEMBL16259478 | 0.81 | EPHX2 (0.47) | MTORCYP2C9CYP2C19 | |
| SCHEMBL15682957 | 0.81 | MTOR (0.54) | MTORMLYCDTACR1P2RX1TMPRSS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345040-B2 | Reverse-turn mimetics and compositions and methods relating thereto | MYRIAD GENETICS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20050250780-A1 | Reverse-turn mimetics and compositions and methods relating thereto | MYRIAD GENETICS, INCORPORATED (US) | 2005-11-10 | — | — | US | disclosed |
| WO-2004035587-A1 | REVERSE-TURN MIMETICS AND COMPOSITION AND METHODS RELATING THERETO | MYRIAD GENETICS, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250780-A1 | Reverse-turn mimetics and compositions and methods relating thereto | TAC3, NTSR1, SCTR | MTOR 1805/4885MLYCD 4584/4885TACR1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.